Login to Your Account

BARDA puts brakes on talks about CBLI’s MCM

By Mari Serebrov
Washington Editor

Thursday, January 23, 2014
Cleveland Biolabs Inc. learned the hard way that there are limits to how much the U.S. government is willing to spend to develop drugs it hopes it will never use. Citing budget constraints, the Biomedical Advanced Research and Development Authority withdrew from negotiations over the company’s proposal to further develop Entolimod (CBLB502) as a medical countermeasure for acute radiation syndrome.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription